GeoVax Labs, Inc. (NASDAQ:GOVX) Q2 2024 Earnings Conference Call August 6, 2024 4:30 PM ET
Company Participants
Max Gadicke - Investor Relations
David Dodd - Chairman & Chief Executive Officer
Mark Reynolds - Chief Financial Officer
Kelly McKee - Chief Medical Officer
Conference Call Participants
Robert LeBoyer - Noble Capital Markets
Jason Kolbert - EF Hutton
Jeff Kraws - Crystal Research
Operator
Good afternoon and welcome everyone to the GeoVax Second Quarter 2024 Corporate Update Call. My name is Alex and I will facilitate today's call.
With me are David Dodd, Chairman and CEO; Mark Reynolds, Chief Financial Officer; Mark Newman, PhD, Chief Scientific Officer; Kelly McKee, MD, MPH, Chief Medical Officer; and John Sharkey, PhD, Vice President, Business Development. [Operator Instructions] As a reminder, this conference is being recorded.
At this time, I am turning the call over to Max Gadicke of Precision HQ [ph].
Max Gadicke
Thank you. Please note the following. Certain statements in this presentation may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act. These statements are based on management's current expectations are subject to uncertainty and changes in circumstances. Actual results may differ materially from those included in these statements due to a variety of factors, including whether, GeoVax can develop and manufacture its product candidates with the desired characteristics in a timely manner and such products will be safe for human use, GeoVax's vaccines will effectively prevent targeted infections in humans, GeoVax's product candidates will receive regulatory approvals necessary to be licensed and marketed, GeoVax raises required capital to complete development of its products, there is development of competitive products that may be more effective or easier to use than GeoVax products, GeoVax will be able to enter into favorable manufacturing and distribution agreements and other factors over which GeoVax has no control.
GeoVax assumes no obligation to update these forward-looking statements and does not intend to do so. More information about these factors is contained in GeoVax's filings with the Securities and Exchange Commission, including those set forth at risk factors in GeoVax's Form 10-K.
It is now my pleasure to introduce the Chairman and CEO of GeoVax, David Dodd.
David Dodd
Thank you, Max. Good afternoon and thank you for participating in the second quarter 2024 GeoVax corporate update call. Following my comments, Mark Reynolds, our CFO, will provide an update of our financials and then your questions will be addressed.